CN111084385A - 一种具有降血糖功效的益生菌制剂的功能性食品 - Google Patents
一种具有降血糖功效的益生菌制剂的功能性食品 Download PDFInfo
- Publication number
- CN111084385A CN111084385A CN202010098967.3A CN202010098967A CN111084385A CN 111084385 A CN111084385 A CN 111084385A CN 202010098967 A CN202010098967 A CN 202010098967A CN 111084385 A CN111084385 A CN 111084385A
- Authority
- CN
- China
- Prior art keywords
- preparation
- functional food
- lactobacillus
- bacterial
- hypoglycemic effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 235000013376 functional food Nutrition 0.000 title claims abstract description 23
- 239000006041 probiotic Substances 0.000 title claims abstract description 23
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 23
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 19
- 239000008280 blood Substances 0.000 title abstract description 27
- 210000004369 blood Anatomy 0.000 title abstract description 27
- 230000001603 reducing effect Effects 0.000 title abstract description 14
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 14
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 14
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 14
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 13
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 13
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 13
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 13
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 13
- 230000001580 bacterial effect Effects 0.000 claims description 38
- 239000000843 powder Substances 0.000 claims description 29
- 238000000855 fermentation Methods 0.000 claims description 23
- 230000004151 fermentation Effects 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 239000010802 sludge Substances 0.000 claims description 12
- 241001052560 Thallis Species 0.000 claims description 11
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 10
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- 235000015193 tomato juice Nutrition 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- 235000005979 Citrus limon Nutrition 0.000 claims description 6
- 244000131522 Citrus pyriformis Species 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 239000004368 Modified starch Substances 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019426 modified starch Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 150000001746 carotenes Chemical class 0.000 claims description 3
- 235000005473 carotenes Nutrition 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 7
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 abstract description 2
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 235000012054 meals Nutrition 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 108091005995 glycated hemoglobin Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001027872 Lactobacillus acidophilus La-14 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种具有降血糖功效的益生菌制剂的功能性食品。它含有罗伊氏乳杆菌(Lactobacillus reuteri)、加氏乳杆菌(Lactobacillus gasseri)、嗜酸乳杆菌(Lactobacillusacidophilus)和乳双歧杆菌(Bifidobacterium lactics)。本发明的具有降血糖功效的益生菌制剂的功能性食品经实验证明，在肥胖模型、糖尿病病人上具有显著降糖(降低早晨空腹血糖、餐后2小时血糖和糖化血红蛋白比例)和有效控制血脂的效果。
Description
技术领域
本发明属于益生菌功能性食品领域，具体涉及一种具有降血糖功效的益生菌制剂的功能性食品。
背景技术
近年来，微生物菌群方面的研究取得日新月异的进展，人类对于微生物菌群与人体特定疾病尤其是慢性疾病之间的紧密关系也有了更加全面的认识。糖尿病是一种常见的代谢紊乱疾病，它除了引起糖代谢紊乱外，还易引起其它严重的急、慢性并发症，严重威胁身体健康。据报告，目前全球有2型糖尿病患者1.3亿，其中我国达4000万人，预测到2020年，全球将增至2.5亿人。目前对糖尿病的治疗上除注射胰岛素外，主要口服降糖药物，如磺酰脲类、双胍类药物和葡萄糖苷酶抑制剂等，但这些药物对肝、肾和胃肠道等脏器损害较大。寻找没有或副作用较轻的治疗糖尿病药物替代物成为研究的重点，尤其是从益生菌或其代谢产物中选择具有降糖功效的菌剂配方，成为目前糖尿病药物发展的主要方向。
发明内容
本发明的目的是提供一种具有降血糖功效的益生菌制剂的功能性食品。
本发明的具有降血糖功效的益生菌制剂的功能性食品，含有罗伊氏乳杆菌(Lactobacillus reuteri)、加氏乳杆菌(Lactobacillusgasseri)、嗜酸乳杆菌(Lactobacillusacidophilus)和乳双歧杆菌(Bifidobacterium lactics)。
所述的具有降血糖功效的益生菌制剂的功能性食品可以制成液体制剂、菌粉制剂或菌片制剂。
所述的功能性食品是将罗伊氏乳杆菌菌泥、加氏乳杆菌菌泥、嗜酸乳杆菌菌泥和乳双歧杆菌菌泥按照cfu比1:1:1:1混合，再用混合菌泥制成液体制剂。所述的液体制剂是将混合菌泥加入到番茄汁和柠檬汁的混合果汁中，混合得到液体制剂。液体制剂中总菌体浓度控制为109cfu/ml。
所述的功能性食品是将罗伊氏乳杆菌、加氏乳杆菌、嗜酸乳杆菌和乳双歧杆菌的发酵液按cfu比1:1:1:1混合，分离菌体和发酵液，菌体冻干制得菌体冻干粉，菌体冻干粉用于制备菌粉制剂或菌粉片剂。
所述的菌粉制剂是将发酵液浓缩10倍后，按每100ml浓缩发酵液与海藻糖5g，可溶性淀粉10g，低聚果糖10g，微晶纤维素30g、蔗糖10g，维生素C5g，改性淀粉5g，麦芽糖5g和菌体冻干粉20g搅拌均匀得到菌粉制剂。
所述的菌粉片剂是每菌体冻干粉20g，加蔗糖10g，维生素C5g，改性淀粉30g，麦芽糖5g，胡萝卜素5g，低聚果糖5g，微晶纤维素20g，混合均匀，压制成片，得到菌粉片剂。
本发明的优势：
1.本发明所用益生菌均是国家添加目录中的益生菌，具有高食品安全性的特性。
2.本发明由不低于10亿(109cfu/g(ml))的益生菌以及其发酵代谢产物组合而成，是一种具有降糖和降脂功能的微生态制剂。
3.本发明的具有降血糖功效的益生菌制剂的功能性食品经实验证明，在肥胖模型、糖尿病病人上具有显著降糖(降低早晨空腹血糖、餐后2小时血糖和糖化血红蛋白比例)和有效控制血脂的效果。
附图说明：
图1是第1周—第16周，每周血糖平均测定值；
图2是第1周-第16周，餐后两小时血糖测定值；
图3是糖化血红蛋白测定值。
具体实施方式：
以下实施例是对本发明的进一步说明，而不是对本发明的限制。
实施例1：
1.液体制剂制备方法：
A、菌种：
a、罗伊氏乳杆菌(Lactobacillus reuteri,美国，ATCC PTA 6475，购买自美国ATCC保藏中心)；
b、加氏乳杆菌(Lactobacillusgasseri美国，购买自Swanson Health Products)；
c、嗜酸乳杆菌(LactobacillusacidophilusLa 14美国，购买自JarrowFormulas)；
d、乳双歧杆菌(Bifidobacterium lacticsBl-04美国，购买自Jarrow Formulas)。
B、发酵培养基(改良MRS培养基)
每1000ml发酵培养基的配置方法如下：将牛肉蛋白粉10克、蛋白胨10克、酵母浸出汁粉5克、葡萄糖10克、乳糖10克、醋酸钠5克、柠檬酸二铵2克、吐温800.1克、硫酸镁0.58克、硫酸锰0.28克、硫酸铵5克、碳酸钙10克、低聚果糖10克、番茄汁200ml混合，然后加蒸溜水至1000ml，调节pH6.2～6.4，用高压锅在118℃灭菌15min。
所述的牛肉蛋白粉和酵母浸出汁粉为市购商品，番茄汁为自制产品。
番茄汁：番茄切碎，加入质量比1:1加入到水中，煮20分钟，滤去残渣，上清液即为番茄汁。
柠檬汁：柠檬切碎，加入质量比1:1加入到水中，煮20分钟，滤去残渣，上清液即为柠檬汁。
分别将罗伊氏乳杆菌、加氏乳杆菌、嗜酸乳杆菌和乳双歧杆菌接种到10ml发酵培养基中，接种时通氮气，37℃静置培养16-24小时，然后再按体积比例1％的接种量接种到1000ml培养基中，接种时通氮气，37℃静置培养16-24小时，然后再按体积比例1％的接种量接种到含1000L发酵培养基的发酵罐中，接种时通氮气，37℃静置培养16-24小时，得到发酵液。
发酵液板框过滤，去清液，余流质菌泥，为菌泥，留作下一步复配。
将柠檬汁和番茄汁按质量比1:1混合，然后加入复合菌泥，混合得到液体制剂，液体制剂中总菌体浓度控制为109cfu/ml。
所述的复合菌泥是将罗伊氏乳杆菌菌泥、加氏乳杆菌菌泥、嗜酸乳杆菌菌泥和乳双歧杆菌菌泥按照cfu比1:1:1:1混合得到。
2.菌粉制剂制备方法：
将步骤1中的各发酵液按cfu比1:1:1:1混合，计算其中总菌种数目计数，离心分离菌体和发酵液。发酵液浓缩，菌体冷冻冻干得菌体冻干粉。其中，发酵液浓缩是将1L发酵液在50～70℃下旋转蒸发浓缩至100ml，然后与海藻糖5g，可溶性淀粉10g，低聚果糖10g，微晶纤维素30g、蔗糖10g，维生素C5g，改性淀粉5g，麦芽糖5g和菌体冻干粉20g搅拌均匀得到菌粉制剂，分装胶囊，胶囊内固体1g,菌粉制剂中总菌数目不少于109cfu/g。
3.菌片制剂制备方法：
上述2中的菌体冻干粉20g，加蔗糖10g，维生素C5g，改性淀粉30g，麦芽糖5g，胡萝卜素5g，低聚果糖5g，微晶纤维素20g，混合均匀，压制成片，每片1g，片剂菌浓度109cfu/g。
4、糖尿病人血糖控制实验：
从第1周开始到第16周，病人每天下午服用步骤1制备的液体制剂100毫升(109cfu/ml)。期间停止服用药物，定期医院体检，每天测定指尖血，一周取一次平均值。
血糖测定：指尖血，测定血糖仪(鱼跃牌悦准II型新款306血糖仪)。
糖化血红蛋白：南方医院门诊化验结果，结果如图1-3所示，从图1可以看出服用后第一周到第十六周空腹血糖明显下降，从图2可以看出第1周到第16周，餐后血糖明显下降，从图3可以看出糖化血红蛋白，在4个月内，由11明显下降到7.4。
Claims (8)
1.一种具有降血糖功效的益生菌制剂的功能性食品，其特征在于，含有罗伊氏乳杆菌(Lactobacillus reuteri)、加氏乳杆菌(Lactobacillus gasseri)、嗜酸乳杆菌(Lactobacillusacidophilus)和乳双歧杆菌(Bifidobacterium lactics)。
2.根据权利要求1所述的具有降血糖功效的益生菌制剂的功能性食品，其特征在于，所述的具有降血糖功效的益生菌制剂的功能性食品为液体制剂、菌粉制剂或菌片制剂。
3.根据权利要求2所述的具有降血糖功效的益生菌制剂的功能性食品，其特征在于，所述的液体制剂、菌粉制剂或菌片制剂中总菌体浓度控制为109cfu/ml。
4.根据权利要求1所述的具有降血糖功效的益生菌制剂的功能性食品，其特征在于，所述的功能性食品是将罗伊氏乳杆菌菌泥、加氏乳杆菌菌泥、嗜酸乳杆菌菌泥和乳双歧杆菌菌泥按照cfu比1:1:1:1混合，再用混合菌泥制成液体制剂。
5.根据权利要求4所述的具有降血糖功效的益生菌制剂的功能性食品，其特征在于，所述的液体制剂是将混合菌泥加入到番茄汁和柠檬汁的混合果汁中，混合得到液体制剂。
6.根据权利要求2或3所述的具有降血糖功效的益生菌制剂的功能性食品，其特征在于，所述的功能性食品是将罗伊氏乳杆菌、加氏乳杆菌、嗜酸乳杆菌和乳双歧杆菌的发酵液按cfu比1:1:1:1混合，分离菌体和发酵液，菌体冻干制得菌体冻干粉，菌体冻干粉用于制备菌粉制剂或菌粉片剂。
7.根据权利要求6所述的具有降血糖功效的益生菌制剂的功能性食品，其特征在于，所述的菌粉制剂是将发酵液浓缩10倍后，按每100ml浓缩发酵液与海藻糖5g，可溶性淀粉10g，低聚果糖10g，微晶纤维素30g、蔗糖10g，维生素C5g，改性淀粉5g，麦芽糖5g和菌体冻干粉20g搅拌均匀得到菌粉制剂。
8.根据权利要求6所述的具有降血糖功效的益生菌制剂的功能性食品，其特征在于，所述的菌粉片剂是每菌体冻干粉20g，加蔗糖10g，维生素C5g，改性淀粉30g，麦芽糖5g，胡萝卜素5g，低聚果糖5g，微晶纤维素20g，混合均匀，压制成片，得到菌粉片剂。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019103150910 | 2019-04-18 | ||
| CN201910315091.0A CN109998113A (zh) | 2019-04-18 | 2019-04-18 | 一种具有降血糖功效的益生菌制剂的功能性食品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111084385A true CN111084385A (zh) | 2020-05-01 |
Family
ID=67172891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910315091.0A Withdrawn CN109998113A (zh) | 2019-04-18 | 2019-04-18 | 一种具有降血糖功效的益生菌制剂的功能性食品 |
| CN202010098967.3A Pending CN111084385A (zh) | 2019-04-18 | 2020-02-18 | 一种具有降血糖功效的益生菌制剂的功能性食品 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910315091.0A Withdrawn CN109998113A (zh) | 2019-04-18 | 2019-04-18 | 一种具有降血糖功效的益生菌制剂的功能性食品 |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN109998113A (zh) |
| WO (1) | WO2020211831A1 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197313A (zh) * | 2020-09-02 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | 具有改善胰岛素抵抗及空腹血糖的益生菌组合物及制备方法 |
| WO2022068273A1 (zh) | 2020-09-29 | 2022-04-07 | 青岛蔚蓝生物股份有限公司 | 一株具有降低血糖功效的凝结芽孢杆菌及其应用 |
| CN114480228A (zh) * | 2022-04-15 | 2022-05-13 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 缓解代谢综合征的益生菌及其代谢产物配方及其应用 |
| CN114984058A (zh) * | 2022-04-15 | 2022-09-02 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 益生菌及其代谢产物（后生元）配方在制备缓解结直肠炎产品中的应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109998113A (zh) * | 2019-04-18 | 2019-07-12 | 广东省微生物研究所（广东省微生物分析检测中心） | 一种具有降血糖功效的益生菌制剂的功能性食品 |
| TWI777475B (zh) * | 2021-03-30 | 2022-09-11 | 豐華生物科技股份有限公司 | 使用乳酸菌菌株組合來治療第1型糖尿病 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110300117A1 (en) * | 2010-06-02 | 2011-12-08 | Genmont Biotech Inc. | Novel Lactobacillus Strain, Composition and Use Thereof for Improving the Syndrome of Diabetes and Complication Thereof |
| CN104887716A (zh) * | 2014-03-07 | 2015-09-09 | 景岳生物科技股份有限公司 | 用于治疗第二型糖尿病的罗伊氏乳杆菌gmnl-89组合物及其用途 |
| CN107156587A (zh) * | 2017-06-05 | 2017-09-15 | 北京天宝瑞健康科技有限公司 | 活性益生菌固体饮料及其在治疗2型糖尿病中应用 |
| CN108783169A (zh) * | 2018-06-25 | 2018-11-13 | 汉臣氏（沈阳）儿童制品有限公司 | 一种四联益生菌固体饮料及其制备方法 |
| CN109481510A (zh) * | 2018-10-11 | 2019-03-19 | 张军毅 | 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784220A (zh) * | 2009-06-19 | 2015-07-22 | 杜邦营养生物科学有限公司 | 治疗糖尿病及相关病症的双歧杆菌 |
| CN102274245B (zh) * | 2010-06-09 | 2014-06-11 | 景岳生物科技股份有限公司 | 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用 |
| CN109998113A (zh) * | 2019-04-18 | 2019-07-12 | 广东省微生物研究所（广东省微生物分析检测中心） | 一种具有降血糖功效的益生菌制剂的功能性食品 |
-
2019
- 2019-04-18 CN CN201910315091.0A patent/CN109998113A/zh not_active Withdrawn
-
2020
- 2020-02-18 CN CN202010098967.3A patent/CN111084385A/zh active Pending
- 2020-04-17 WO PCT/CN2020/085252 patent/WO2020211831A1/zh active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110300117A1 (en) * | 2010-06-02 | 2011-12-08 | Genmont Biotech Inc. | Novel Lactobacillus Strain, Composition and Use Thereof for Improving the Syndrome of Diabetes and Complication Thereof |
| CN104887716A (zh) * | 2014-03-07 | 2015-09-09 | 景岳生物科技股份有限公司 | 用于治疗第二型糖尿病的罗伊氏乳杆菌gmnl-89组合物及其用途 |
| CN107156587A (zh) * | 2017-06-05 | 2017-09-15 | 北京天宝瑞健康科技有限公司 | 活性益生菌固体饮料及其在治疗2型糖尿病中应用 |
| CN108783169A (zh) * | 2018-06-25 | 2018-11-13 | 汉臣氏（沈阳）儿童制品有限公司 | 一种四联益生菌固体饮料及其制备方法 |
| CN109481510A (zh) * | 2018-10-11 | 2019-03-19 | 张军毅 | 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197313A (zh) * | 2020-09-02 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | 具有改善胰岛素抵抗及空腹血糖的益生菌组合物及制备方法 |
| CN113197313B (zh) * | 2020-09-02 | 2023-10-27 | 内蒙古蒙牛乳业（集团）股份有限公司 | 具有改善胰岛素抵抗及空腹血糖的益生菌组合物及制备方法 |
| WO2022068273A1 (zh) | 2020-09-29 | 2022-04-07 | 青岛蔚蓝生物股份有限公司 | 一株具有降低血糖功效的凝结芽孢杆菌及其应用 |
| CN114480228A (zh) * | 2022-04-15 | 2022-05-13 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 缓解代谢综合征的益生菌及其代谢产物配方及其应用 |
| CN114984058A (zh) * | 2022-04-15 | 2022-09-02 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 益生菌及其代谢产物（后生元）配方在制备缓解结直肠炎产品中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109998113A (zh) | 2019-07-12 |
| WO2020211831A1 (zh) | 2020-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111084385A (zh) | 一种具有降血糖功效的益生菌制剂的功能性食品 | |
| CN108157973B (zh) | 一种有益糖脂代谢功能的益生菌组合物及其制剂和应用 | |
| TWI709374B (zh) | 包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物之用途 | |
| CN110150669B (zh) | 一种适于糖尿病患者食用的益生菌组合物及其应用 | |
| TWI645854B (zh) | 胚芽乳酸桿菌tci378及其於減脂及改善腸胃功能之應用 | |
| CN111346114A (zh) | 罗伊氏乳杆菌的用途 | |
| WO2014068338A1 (en) | Diverticulitis treatment | |
| JP2010132625A (ja) | 抗糖尿病剤 | |
| CN113583903A (zh) | 一种预防或治疗ii型糖尿病的微生物组合物及其制备方法和应用 | |
| US20120301505A1 (en) | Immunostimulating Agent and Method for Production Thereof | |
| CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
| CN115210359A (zh) | 利用红参促进乳酸菌增殖的培养工艺 | |
| CN108795823B (zh) | 一种改善女性孕产妇肠道菌群的益生菌的培养方法和应用 | |
| KR101468698B1 (ko) | 3단 발효 공법을 통한 장내균총 개선 소재의 개발 | |
| KR102048434B1 (ko) | 무청 고분자 분획물을 포함하는 장내 균총 개선용 조성물 | |
| TWI667344B (zh) | Lactobacillus reuteri strain GMNL-263 and composition thereof capable of improving hypertension | |
| US20190388484A1 (en) | Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof | |
| CN109674060B (zh) | 一种具有辅助缓解二型糖尿病功能的益生菌膳食补充剂及其应用 | |
| CN112089054A (zh) | 降血糖益生菌组合物 | |
| TWI817342B (zh) | 益生質組合物及其用途 | |
| CN106974940B (zh) | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 | |
| KR20200075724A (ko) | 무청 추출물을 포함하는 장내 균총 개선용 조성물 | |
| US20230144246A1 (en) | Probiotic composition and its method for improving intestinal tract of subject in need thereof | |
| US11911421B2 (en) | Probiotic composition including lactic acid bacterial strains and use thereof | |
| KR102500796B1 (ko) | 케피어 유래 유산균의 세포표면단백질을 포함하는 비만의 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200501 |